Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 6/2007

01-06-2007 | Short communication

[1-11C]Acetate uptake is not increased in renal cell carcinoma

Authors: J. Kotzerke, C. Linné, M. Meinhardt, J. Steinbach, M. Wirth, G. Baretton, N. Abolmaali, B. Beuthien-Baumann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2007

Login to get access

Abstract

Purpose

The purpose of this study was to investigate the potential of [1-11C]acetate (AC) as a metabolic tracer for renal cell cancer in human subjects.

Methods

Twenty-one patients with suspected kidney tumours were investigated with AC and dynamic PET. AC uptake was scored on a five-step scale. Tumour localisation was known from CT/MRI. Histology was available in 18/21 patients. The results in these 18 patients are reported.

Results

AC uptake by the tumour was less than (n = 11), equal to (n = 5) or higher than (n = 2) uptake in the surrounding renal parenchyma. Histological tumour types showed a typical distribution, with a predominance of clear cell carcinomas (n = 14) and only a small number of papillary cell carcinomas (n = 2) and oncocytomas (n = 2). Only the benign oncocytomas were highly positive with AC.

Conclusion

In most kidney tumours the AC accumulation was not higher than in normal kidney parenchyma. Therefore, AC PET cannot be recommend for the characterisation of a renal mass.
Literature
1.
Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274–92.PubMedCrossRef
2.
Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for 11C-acetate whole-body PET. J Nucl Med 2004;45:1233–6.PubMed
3.
Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213–21.PubMed
4.
Yeh SH, Liu RS, Wu LC, Yen SH, Chang CW, Chen KY. 11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun 1999;20:131–4.PubMedCrossRef
5.
Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, et al. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET. Eur J Nucl Med Mol Imaging 2004;31:13–21.PubMedCrossRef
6.
Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995;36:1595–601.PubMed
7.
Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380–4.PubMedCrossRef
8.
Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125–43.PubMed
9.
Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987–9.PubMedCrossRef
10.
Shriki J, Murthy V, Brown J. Renal oncocytoma on 1-11C acetate positron emission tomography: case report and literature review. Mol Imaging Biol 2006;8:208–11.PubMedCrossRef
11.
Blake MA, McKernan M, Setty B, Fischman AJ, Mueller PR. Renal oncocytoma displaying intense activity on 18F-FDG PET. AJR Am J Roentgenol 2006;186:269–70.PubMedCrossRef
12.
Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996;35:146–50.PubMed
Metadata
Title
[1-11C]Acetate uptake is not increased in renal cell carcinoma
Authors
J. Kotzerke
C. Linné
M. Meinhardt
J. Steinbach
M. Wirth
G. Baretton
N. Abolmaali
B. Beuthien-Baumann
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0362-5

Other articles of this Issue 6/2007

European Journal of Nuclear Medicine and Molecular Imaging 6/2007 Go to the issue

Original Article

99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits

Molecular Imaging

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging

Book review

Eric Hall and Amato J. Giaccia: Radiobiology for the radiologist, 6th edn.

Society communications

Society communications

Letter to the editor

Radioguided localisation (ROLL) of non-palpable breast lesions and simultaneous sentinel lymph node biopsy (SNOLL): the experience of the European Institute of Oncology

Announcement

Announcement